Application of PHF20 in the preparation of tumor diagnostic, prognostic assessment products and tumor therapeutic drugs
By using the PHF20 gene as a target, detecting its expression level, and designing inhibitors, the challenges of early diagnosis and treatment of gastric cancer have been solved, enabling personalized treatment and improved prognosis for gastric cancer.
Patent Information
- Application Number
- CN202611269825.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-20
- Publication Date
- 2026-11-17
AI Technical Summary
Current technology lacks effective methods for early diagnosis of gastric cancer, resulting in many patients being diagnosed at an advanced stage, making treatment difficult and failing to significantly improve patient prognosis.
Using the PHF20 gene as a target for tumor diagnosis and treatment, we screen the incidence and prognosis of tumors by detecting its expression level. We design inhibitors such as shRNA and Torachrysone 8-glucoside to inhibit the expression of the PHF20 gene, interfere with the function of the PHF20 protein, and prepare drugs for tumor diagnosis and treatment.
It has improved the early diagnosis of gastric cancer, provided personalized treatment plans, significantly inhibited the proliferation and metastasis of gastric cancer cells, and prolonged disease-free survival.
Smart Images

Figure CN123108147A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedicine, and in particular to the application of PHF20 in the preparation of tumor diagnostic, prognostic assessment products and tumor therapeutic drugs. Background Technology
[0002] Gastric cancer is one of the most common malignant tumors, ranking among the top in both incidence and mortality. Notably, in recent years, the incidence of gastric cancer has shown a trend towards affecting younger people, with the incidence rate gradually increasing in younger populations. The prevention and treatment of gastric cancer faces severe challenges, mainly reflected in the characteristics of "three highs and three lows": "three highs" refer to high incidence, high metastasis rate, and high mortality rate; "three lows" refer to low early diagnosis rate, low radical resection rate, and low 5-year survival rate. Despite continuous advancements in treatment methods such as surgery, chemotherapy, and radiotherapy in recent years, the overall prognosis for gastric cancer patients remains unsatisfactory, with a 5-year overall survival rate of only about 10-20%. The key reason for this predicament lies in the lack of effective early diagnostic methods. Many patients are diagnosed at an advanced stage, and when the tumor has locally invaded or metastasized to distant sites, the difficulty of treatment is extremely high. Therefore, in-depth exploration of key genes related to the occurrence and development of gastric cancer is of great significance for elucidating its pathogenesis, improving early diagnosis, and developing new treatment strategies.
[0003] PHF20 (Plant Homeodomain Finger Protein 20) is a multifunctional protein containing a Tudor domain and a plant homeodomain (PHD), enabling it to recognize and bind specific methylated lysine residues on histones, thereby participating in chromatin remodeling and transcriptional regulation. It is a component of the MOF histone acetyltransferase complex, involved in regulating the acetylation of histone H4 at multiple lysine sites. PHF20 participates in regulating cell differentiation. During osteoblast differentiation, PHF20 expression gradually increases, promoting osteogenic gene expression and cellular mineralization through direct binding to Runx2 and enrichment of its promoter region's H3K4me3 histone modification. PHF20 knockout mice exhibit skeletal defects and hematopoietic abnormalities, leading to postnatal death. Summary of the Invention
[0004] To overcome the shortcomings and deficiencies of the existing technology, the purpose of this invention is to provide the application of the PHF20 gene in the preparation of products for tumor diagnosis.
[0005] Another object of the present invention is to provide the application of the PHF20 gene in the preparation of products for tumor treatment.
[0006] The objective of this invention is achieved through the following technical solution:
[0007] Application of the PHF20 gene in the preparation of tumor diagnostic products.
[0008] Application of the PHF20 gene in the preparation of tumor prognostic assessment products.
[0009] A biomarker for screening the probability of tumor incidence and prognostic assessment, including the expression level of the PHF20 gene.
[0010] High expression of the PHF20 gene indicates a high probability of tumor development and a poor prognosis.
[0011] A tumor diagnostic product, comprising reagents for detecting the expression level of the PHF20 gene.
[0012] Application of reagents that inhibit PHF20 gene expression in the preparation of tumor therapeutic drugs.
[0013] The nucleotide sequence of the PHF20 gene is shown in SEQ ID NO.1.
[0014] An shRNA that inhibits the expression of the PHF20 gene, comprising at least one of the following:
[0015] shPHF20#1, its positive strand nucleotide sequence is: 5'-TGCTGGGACAGTCCTTATTTA-3'
[0016] The antisense strand nucleotide sequence is: 5'-TAAATAAGGACTGTCCCAGCA-3'
[0017] shPHF20#2, its positive strand nucleotide sequence is: 5'-GTGGGTAATGCTAGGCCTAAA-3'
[0018] The antisense strand nucleotide sequence is: 5'-TTTAGGCCTAGCATTACCCAC-3'
[0019] Analogs of shPHF20#1 or shPHF20#2 that still retain the function of inhibiting PHF20 gene expression, obtained through base insertion, deletion, or substitution.
[0020] The shRNA that inhibits PHF20 gene expression is ligated into a vector, packaged with a lentivirus, and transfected into cells. It can recognize and degrade the mRNA transcribed from the PHF20 gene through an RNA interference mechanism, thereby knocking down the expression of PHF20 protein at the post-transcriptional level, resulting in the inability (or reduction) of normal PHF20 protein formation.
[0021] A vector for inhibiting PHF20 gene expression, comprising the nucleotide sequence of the shRNA described above for inhibiting PHF20 gene expression.
[0022] The application of the shRNA that inhibits PHF20 gene expression and / or the vector that inhibits PHF20 gene expression in the preparation of tumor therapeutic drugs.
[0023] Application of Torachrysone 8-glucoside in the preparation of PHF20 egg inhibitor.
[0024] The Torachrysone 8-glucoside can inhibit the activity of PHF20 by binding to it and interfering with the interaction between PHF20 and CUL4B.
[0025] Application of Torachrysone 8-glucoside in the preparation of tumor therapeutic drugs.
[0026] The structural formula of Torachrysone 8-glucoside is shown below:
[0027] .
[0028] One PHF20 inhibitor includes Torachrysone 8-glucoside.
[0029] A tumor treatment drug comprising the above-mentioned shRNA that inhibits PHF20 gene expression, a vector that inhibits PHF20 gene expression, and / or Torachrysone 8-glucoside.
[0030] The aforementioned tumor treatment drugs also include pharmaceutically acceptable carriers.
[0031] The tumor in question is stomach cancer.
[0032] The present invention has the following advantages and effects compared with the prior art:
[0033] This invention, through data analysis and clinical specimen validation, discovered that PHF20 is highly expressed in gastric cancer samples, and gastric cancer patients with low PHF20 expression have longer disease-free survival. PHF20 promotes the proliferation and metastasis of gastric cancer cells. This invention also predicted the three-dimensional structure, active site, active pocket, and possible inhibitors of the PHF20 protein. Furthermore, related experiments validated that the natural compound Torachrysone 8-glucoside, a PHF20 inhibitor, can effectively inhibit the proliferation and metastasis of gastric cancer cells. This invention opens up new directions for personalized treatment of gastric cancer. Attached Figure Description
[0034] Figure 1This is the result of the differential expression screening of PHF20 in gastric cancer and normal tissues in Example 1; where A. the data comes from normal tissue data and gastric cancer tissue data in the TCGA database, wherein * This indicates that p < 0.05. ** This indicates that p < 0.01. *** A. Indicates p < 0.001. B. ROC curve, showing that PHF20 expression in the TCGA database gastric cancer dataset can effectively predict the survival of gastric cancer patients, p < 0.001. C. Survival curve, showing the relationship between PHF20 expression level and overall survival, time to first progression, and post-progression survival in gastric cancer patients.
[0035] Figure 2 The expression levels of PHF20 in the GEO database and clinical samples in Example 1 are shown; wherein: A. PHF20 is highly expressed in gastric cancer tissues in the gastric cancer dataset downloaded from the GEO database, wherein **** A. Indicates p<0.0001; B. Collect clinical gastric cancer and adjacent normal samples, and detect the expression level of PHF20 by real-time quantitative PCR and immunoblotting.
[0036] Figure 3 The figure shows the results of the EdU experiment in Example 2, which detected the effect of PHF20 expression level on cell proliferation. In the figure: A is a fluorescence microscope image; B is the quantification of the results in Figure A.
[0037] Figure 4 The figure shows the experimental results of the effect of PHF20 expression level on the clonogenic ability of tumor cells in Example 2.
[0038] Figure 5 The figure shows the results of the Trans-well experiment in Example 2, which clarified the effect of PHF20 expression level on the invasive ability of tumor cells.
[0039] Figure 6 Example 2 shows the interference efficiency of two shRNAs (shPHF20#1, shPHF20#2) of PHF20 and the overexpression efficiency of the PHF20 overexpression vector in two gastric cancer cell lines (AGS and HGC-27).
[0040] Figure 7 This is a predicted three-dimensional structure diagram, active site, and active pocket of the PHF20 protein in Example 3.
[0041] Figure 8The following are the compounds most likely to inhibit PHF20 as screened in Example 3: Hydrogangel 8-O-glucoside, Pulmatin, Torachrysone 8-glucoside, and Vilanterol trifenatate, along with their respective 3D structures docking with the PHF20 protein; wherein: A. 2D and 3D diagrams showing the predicted binding of Hydrogangel 8-O-glucoside to PHF20. B. 2D and 3D diagrams showing the predicted binding of Pulmatin to PHF20. C. 2D and 3D diagrams showing the predicted binding of Torachrysone 8-glucoside to PHF20. D. 2D and 3D diagrams showing the predicted binding of Vilanterol trifenatate to PHF20.
[0042] Figure 9 The figure shows the experimental results of the efficacy verification of the PHF20 inhibitor in Example 4. Both Torachrysone 8-glucoside and Vilanterol trifenatate inhibitors affect the binding of PHF20 to CUL4B.
[0043] Figure 10 This is a diagram showing the experimental results of the antitumor effect verification of the PHF20 inhibitor Torachrysone 8-glucoside in Example 4.
[0044] Figure 11 This is a graph showing the experimental results of the antitumor effect verification of the PHF20 inhibitor Vilanterol trifenatate in Example 4.
[0045] Figure 12 In Example 4, the PHF20 inhibitor Vilanterol trifenatate exerts its anti-tumor effect by inducing ferroptosis in tumor cells. Detailed Implementation
[0046] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the embodiments of the present invention are not limited thereto.
[0047] Example 1: Screening of candidate genes
[0048] 1.1 TCGA Database Filtering
[0049] The expression differences of the PHF20 gene in gastric cancer tissues and normal tissues were obtained from the TCGA database. Figure 1As shown in the figure, the PHF20 gene was significantly highly expressed in gastric cancer tissue (p < 0.01). PHF20 gene expression levels and patient survival time / status were extracted from the TCGA database, and ROC curves were plotted using MEDCalc software. As shown in the figure, the area under the ROC curve in the prediction model was 0.803 (p < 0.001), indicating that the PHF20 gene can effectively predict the survival of gastric cancer patients. Furthermore, survival analysis revealed that the expression level of PHF20 was significantly correlated with overall survival, time to first progression, and post-progression survival in gastric cancer patients (P values all < 0.005).
[0050] 1.2 GEO Database Filtering
[0051] Further analysis was conducted using a gastric cancer dataset obtained from the GEO database to determine the expression level of the PHF20 gene in both gastric cancer and normal tissues. Results are as follows: Figure 2 As shown, the PHF20 gene was found to be highly expressed in gastric cancer tissues in the GSE66229, GSE13911, GSE33429, and GSE29272 datasets (p<0.0001).
[0052] 1.3 Clinical Sample Validation
[0053] Ten gastric cancer tissues and normal bile duct tissues were collected, and proteins were extracted. The expression levels of PHF20 and the internal reference GAPDH were detected by Western blotting. The results showed that PHF20 was significantly highly expressed in gastric cancer tissues.
[0054] Based on the above experimental results, PHF20 is suggested to be a potential target for the diagnosis and treatment of gastric cancer. Therefore, further experiments should be designed around this gene to verify its efficacy.
[0055] Example 2: Design of interference vector to verify PHF20 gene function
[0056] 2.1 Design and Transfection of Interference Vectors
[0057] To verify the specific effects of PHF20 gene expression in cells, Shanghai Gemma Company was commissioned to synthesize viral vectors containing shNC (negative control), shPHF20 (interference vector), and PHF20 (overexpression vector), as well as a blank vector. The interference lentiviral vectors were LV3(H1 / GFP&Puro) and LV3(H1 / GFP&Puro), and the overexpression lentiviral vector was LV5(EF-1a / GFP&Puro), which were used for cell experiments.
[0058] The nucleotide sequence of shPHF20#1 is as follows:
[0059] Chain of Justice: 5'-TGCTGGGACAGTCCTTATTTA-3';
[0060] Antonym chain: 5'-TAAATAAGGACTGTCCCAGCA-3';
[0061] The nucleotide sequence of shPHF20#2 is as follows:
[0062] Chain of Justice: 5'-GTGGGTAATGCTAGGCCTAAA-3';
[0063] Antonym: 5'-TTTAGGCCTAGCATTACCCAC-3';
[0064] The nucleotide sequence of shSCR is as follows:
[0065] Chain of Justice: 5'-TTCTCCGAACGTGTCACGT-3'
[0066] Antonym chain: 5'-ACGTGACACGTTCGGAGAA-3'
[0067] Following the kit instructions, well-grown gastric cancer cell lines AGS and HGC-27 (purchased from the Shanghai Cell Bank) were digested, counted, and seeded into six-well plates. 2 ml of culture medium was added to each well to ensure cell confluence was between 40% and 60% the day after infection. The required virus volume was calculated as [(MOI × cell number) / virus titer (TU / ml)] × 1000. The following day, the virus was removed from -80°C and thawed on ice. Simultaneously, the cells were removed, and the original culture medium in each well was discarded. Prepared virus-containing culture medium was added to each well. This medium consisted of the calculated virus solution (shSCR, shPHF20#1, shPHF20#2, Vector, PHF20), with a final concentration of 5 µg / ml of Polybrene. Finally, complete culture medium was added to bring each well to 100 µl. The cells with the changed medium were placed in a 37°C, 5% CO2 incubator and cultured for 24 hours. The medium was changed again, and the fluorescence expression was observed under a fluorescence microscope. Puromycin was added at appropriate times (usually 24-48 hours) to screen out cells that were stably infected with the virus for subsequent experiments.
[0068] 2.2 EdU assay to detect the effect of PHF20 expression on cell proliferation ability
[0069] AGS cell lines infected with the corresponding viral vector were cultured to the logarithmic growth phase, and then divided into two groups of cells at 1 × 10⁶ cells per well. 5The cells were seeded at a density of 100% into 6-well plates. After overnight cell adhesion, they were incubated with 5-ethynyl-2'-deoxyuridine (EdU) for 2 hours, washed twice with PBS, destained with 4% paraformaldehyde and fixed on a shaker for 30 minutes, incubated with 2 mg / mL glycine for 5 minutes to neutralize the paraformaldehyde, incubated with permeate for 10 minutes, washed twice with PBS, added 1× Apollo staining solution, and incubated on a shaker at room temperature in the dark for 30 minutes. They were then washed 2-3 times with permeate for 10 minutes each time, stained with DAPI for 10 minutes, washed 2-3 times with PBS, and observed and photographed using a fluorescence microscope.
[0070] Experimental results are as follows Figure 3 As shown, compared with the control, cell proliferation was significantly reduced after PHF20 interference and significantly enhanced after PHF20 overexpression, demonstrating that the expression level of PHF20 is positively correlated with the proliferation of tumor cells.
[0071] 2.2 Effect of PHF20 expression on tumor cell clonogenic ability
[0072] The clonogenic capacity of stable PHF20-interfered gastric cancer cell lines AGS and HGC-27, along with corresponding control cells, was analyzed. The specific steps were as follows: Cells were counted and passaged into 6-well plates (5000 cells per well), incubated at 37°C for 10-14 days, with medium changed every two days. Upon harvesting, cells were washed twice with PBS, fixed with 4% paraformaldehyde at room temperature for 10 minutes, washed twice with PBS, stained with 0.1% crystal violet for 20 minutes, rinsed thoroughly with PBS, and then photographed for observation.
[0073] The results are as follows Figure 4 As shown, after interfering with PHF20, the number of clones formed by gastric cancer cells was significantly reduced, and the cell proliferation capacity was significantly decreased.
[0074] 2.3 Trans-well assay to verify the effect of PHF20 expression on tumor cell invasion ability
[0075] The human gastric cancer cell lines AGS and HGC-27, which stably express shSCR (negative control), shPHF20, vector, and PHF20, respectively, were used in the experiment for trans-well assays. The steps are as follows:
[0076] First, place the chambers into a culture plate, add serum-free medium to rehydrate the matrix gel, then digest the cells, and add 2×10⁶ cells. 4Cells were resuspended in 300 μL of serum-free medium and injected into the upper chamber. 500 μL of serum-containing medium was added to the 24-well lower chamber, ensuring there were no air bubbles between the chamber and the lower medium layer. Cells were cultured for 12–48 hours, then fixed with paraformaldehyde for 30 minutes, washed twice with PBS, stained with crystal violet for 20 minutes, washed twice with PBS, air-dried, and observed and counted under an inverted microscope.
[0077] The results are as follows Figure 5 As shown, interference with PHF20 significantly reduced the invasive ability of gastric cancer cells, while overexpression of PHF20 significantly enhanced the invasive ability of gastric cancer cells, demonstrating that the expression level of PHF20 is positively correlated with the invasive ability of tumor cells.
[0078] 2.4 Detection of PHF20 interference efficiency and overexpression efficiency
[0079] The human gastric cancer cell lines AGS and HGC-27, which stably express shSCR (negative control), shPHF20#1, shPHF20#2, vector, and PHF20, respectively, were used in the experiment. Real-time quantitative PCR and Western blotting experiments were performed to detect PHF20 levels in these cells. The experimental steps are as follows:
[0080] Real-time quantitative PCR: Cells were lysed, total RNA was extracted and quantified, and then reverse transcription was performed to obtain cDNA. The reaction mixture was then prepared on ice, including cDNA template, upstream and downstream specific primers, a quantitative real-time PCR mixture (containing Taq enzyme, dNTPs, and SYBR Green fluorescent dye), and enzyme-free water. The reaction plate was then placed in a PCR instrument for PCR, following a pre-denaturation-denaturation-annealing-extension cycle (40 cycles) followed by melting curve analysis.
[0081] Western Blot: Lyse total cell protein, centrifuge and collect supernatant, determine protein concentration using the BCA method, calculate the loading volume, add protein loading buffer and boil for denaturation. Perform SDS-PAGE electrophoresis on the protein sample, transfer to a membrane, then place the membrane in 5% skim milk blocking buffer and incubate at room temperature for 1-2 hours. After washing with TBST, cut the membrane, add the corresponding primary antibody and incubate overnight at 4°C; then wash the membrane with TBST to remove unbound primary antibody, incubate with secondary antibody for 1 hour, wash thoroughly with TBST, and then perform imaging.
[0082] The results are as follows Figure 6 As shown, interference with PHF20 significantly reduced both its mRNA and protein levels, and shPHF20#2 exhibited superior interference efficiency compared to shPHF20#2. Overexpression of PHF20 significantly increased both its intracellular mRNA and protein levels.
[0083] Example 3
[0084] 3.1 Prediction of PHF20 crystal structure and active pocket
[0085] The amino acid sequence of human PHF20 was obtained using uniprot, and the protein crystal structure was predicted using AlphaFold3. The obtained protein crystals were processed using the Protein Preparation Wizard module of Schrödinger software for protein preprocessing, regenerating states of native ligands, H-bond assignment optimization, protein energy minimization, and water removal. The 2D SDF structure files of the natural compound library were processed using the LigPrep module in Schrödinger to generate all 3D chiral conformations. The QikProp module was used to predict the ADME / T parameter scores of the ligands, obtaining a total of 51 types of parameters. The evaluation primarily followed the Lipinski five principles. The SiteMap module in Schrödinger was first used to predict the optimal binding site, and then the Receptor Grid Generation module in Schrödinger was used to set the most suitable enclosing box to perfectly enclose the predicted binding site, thus obtaining the active site of the PHF20 protein.
[0086] The results are as follows Figure 7 The diagram shows the 2D structure of PHF20, where the white dots represent the active sites and the red box indicates the location of the tudor domain 4-147AA, which is the location of the active pocket.
[0087] 3.2 Screening of PHF20 inhibitors
[0088] Molecular docking was performed on the active site of PHF20 using comprehensive compound libraries (Selleck FDA-Approved Drug Library, catalog number: L1300; TargetMol Natural Compound Library, catalog number: L6000; MedChemExpress Natural Product Library, catalog number: HY-L021; Pharmacodia Natural Product Library, BioBioPha BBP Natural Product Library, APExBIO Anti-cancer Compound Library Plus, catalog number: L1023; Selleck Preclinical / Clinical Compound Library, catalog number: L2000; MedChemExpress Immunology / Inflammation Compound Library, catalog number: HY-L007). The lower the score, the lower the binding free energy of the compound to the protein, and the higher the binding stability. The MM-GBSA calculation analysis was performed on the active site of the ligand with the lowest score for PHF20 protein. The lower the score, the higher the stability of the ligand binding to PHF20 protein. The four compounds with the lowest scores were selected for further verification. We purchased four compounds for subsequent experiments: Hydrogran 8-O-glucoside (Chemical Book, catalog number 67600-94-6), Vilanterol Trifenatate (MCE, catalog number 503070-58-4), Pulmatin (Emodin-1-glucoside, catalog number B20239), and Torachrysone 8-glucoside (Emodin-8-O-glucoside, catalog number 64032-49-1).
[0089] The results are as follows Figure 8 As shown, further molecular docking prediction results revealed that all four compounds, Hydrogangel 8-O-glucoside, Vilanterol Trifenatate, Pulmatin, and Torachrysone 8-glucoside, bound to PHF20, demonstrating their potential therapeutic activity. Further verification of the effects of these four compounds will be conducted in the future.
[0090] Example 4: Efficacy Verification Experiment of PHF20 Inhibitor
[0091] 4.1 Verification of the inhibitory effect of PHF20 inhibitor on tumor cell proliferation
[0092] The inhibitory effects of the natural products (Hydrangel 8-O-glucoside, Pulmatin, Torachrysone 8-glucoside, Vilanterol Trifenatate) screened in Example 4 on gastric cancer cells were verified using the CCK8 assay. Gradient concentrations were set to verify their IC50. The toxic effects of these natural products on gastric cancer cells were detected by MTT assay after 24 hours.
[0093] Experimental results are as follows Figure 9 As shown in Figures A and B, the results indicate that Torachrysone 8-glucoside and Vilanterol Trifenatate significantly inhibited the proliferation of gastric cancer cells and had a strong killing effect on gastric cancer cells. Their half-maximal inhibitory concentrations (IC50) against gastric cancer cells AGS and HGC-27 were 331.2 µM, 319.1 µM and 61.31 µM, 30.69 µM, respectively.
[0094] 4.2 Cell safety experiments
[0095] Following the method described in 4.1, the toxic effects of Torachrysone 8-glucoside and Vilanterol Trifenatate on normal human gastric mucosal epithelial cells (GES-1) were detected using the CCK8 assay.
[0096] Experimental results are as follows Figure 9 As shown in Figure C, the results indicate that Torachrysone 8-glucoside and Vilanterol Trifenatate have low cytotoxicity to normal cells and are safe for use.
[0097] 4.3 Immunoprecipitation for protein-protein interactions
[0098] AGS and HGC-27 gastric cancer cells were treated with the selected compounds (Hydrangel 8-O-glucoside, Pulmatin, Torachrysone 8-glucoside, Vilanterol Trifenatate), respectively. After 24 hours, the cells were harvested and immunoprecipitation experiments were performed to detect the interaction between the two proteins.
[0099] Experimental results are as follows Figure 9As shown in Figure D, the results indicate that both Torachrysone 8-glucoside and Vilanterol Trifenatate can interfere with the interaction between PHF20 and CUL4B, and this interaction is significantly dose-dependent.
[0100] 4.4 Verification of the antitumor effect of Torachrysone 8-glucoside, a natural compound inhibitor of PHF20.
[0101] Following the method in Example 2, the gastric cancer cell lines AGS and HGC-27 were treated with Torachrysone 8-glucoside, and the effects on the proliferation and invasion abilities of gastric cancer cells were verified by combining EdU and Tranwell experiments.
[0102] Experimental results are as follows Figure 10 As shown in Figures A through D, the results indicate that treatment with Torachrysone 8-glucoside significantly inhibits the proliferation and metastasis of gastric cancer cells, and the inhibitory effect increases with increasing concentration.
[0103] 4.5 Nude mouse tumorigenesis experiment to verify the anti-cancer effect of the natural product Torachrysone 8-glucoside
[0104] The antitumor activity of Torachrysone 8-glucoside in vivo was detected using a nude mouse tumorigenesis assay. AGS cells stably overexpressing PHF20 in the logarithmic growth phase were digested, centrifuged, resuspended in phosphate-buffered saline (PBRS), and kept on ice. 4–6 week old BALB / c nude mice were selected and injected intraperitoneally with an equal volume of cell suspension to establish a subcutaneous xenograft model. Mice were randomly divided into a control group and a drug treatment group. The mice were housed in an SPF-protected environment, and their mental state and weight were observed regularly. Once subcutaneous tumors were visibly formed and the tumor volume was expected to reach 100–150 mm³ in 7–14 days, subsequent intervention began. Torachrysone 8-glucoside was administered intraperitoneally at a dose of 4 mg / kg / day, while the control group received an equal volume of saline. Treatment was administered once daily for 21 consecutive days. Mice were then sacrificed, and tumor tissue was extracted for measurement and comparison of tumor volume and weight.
[0105] Experimental results are as follows Figure 10 As shown in Figures E to F, the results indicate that the tumor tissue volume was significantly reduced in the treatment group with the natural product Torachrysone 8-glucoside, suggesting that it has a significant anti-tumor effect.
[0106] 4.6 Verification of the antitumor effect of the PHF20 inhibitor Vilanterol Trifenatate
[0107] Following the method in Example 2, gastric cancer cell lines AGS and HGC-27 were treated with Vilanterol Trifenatate, and the effects on the proliferation and invasion abilities of gastric cancer cells were verified by combining clonogenic assays and tranwell assays.
[0108] Experimental results are as follows Figure 11 As shown in Figures A and B, the results indicate that treatment with Vilanterol Trifenatate significantly inhibits the proliferation and metastasis of gastric cancer cells, and the inhibitory effect increases with increasing concentration.
[0109] 4.7 The PHF20 inhibitor Vilanterol Trifenatate exerts its antitumor effect by promoting ferroptosis.
[0110] Lipid peroxidation was assessed using confocal BODIPY staining and flow cytometry BODIPY staining.
[0111] Confocal BODIPY staining was used to assess lipid peroxidation: AGS and HGC-27 gastric cancer cells were seeded in confocal culture dishes. After cell confluence reached 60%–70%, cells were treated with different doses of Vilanterol, or divided into Control, Vilanterol monotherapy, Vilanterol+Fer-1, and Vilanterol+Lipro groups. Cells were pretreated with Fer-1 or Lipro 2 h before incubation with Vilanterol for 12 h. The control group received an equal volume of solvent. After discarding the culture medium, cells were washed three times with pre-cooled PBS, and then incubated with serum-free medium containing 10 μM C11-BODIPY 581 / 591 probes at 37 ℃ in the dark for 30 min. After washing again with PBS to remove free probes, images were directly acquired using a laser confocal microscope. Green fluorescence (Non-ox) of reduced lipids at an excitation wavelength of 488 nm, red fluorescence (ox) of oxidized lipids at an excitation wavelength of 561 nm, and dual-channel superimposed Merge were collected. Images, with a uniform scale of 20 μm.
[0112] Flow cytometry-based BODIPY staining was used to assess lipid peroxidation: Human gastric cancer AGS and HGC-27 cells were seeded in cell culture dishes and treated with different doses of Vilanterol, or the cells were divided into four groups: a blank control group (Control), a Vilanterol monotherapy group, a Vilanterol + Ferrostatin-1 (Fer-1) complementation group, and a Vilanterol + Liproxstatin-1 (Lipro) complementation group. Pretreatment: Cells were incubated with the ferroptosis inhibitor Fer-1 and the lipid antioxidant Lipro for 2 h beforehand, followed by treatment with Vilanterol for 12 h; the control group received an equal volume of drug solvent. After drug treatment, the culture medium was discarded, cells were washed twice with pre-cooled PBS, and single-cell suspensions were collected by trypsin digestion with 0.25% trypsin. The cells were centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cell pellet was resuspended in PBS and washed. Prepare a 10 μM C11-BODIPY581 / 591 staining working solution, resuspend the cells, and incubate at 37 ℃ in the dark for 30 min. After incubation, wash with PBS to remove unbound free probes, and immediately resuspend the cells for flow cytometry analysis.
[0113] Figure 12 Confocal BODIPY staining results showed that after Vilanterol treatment, lipid oxidation products (green fluorescence) were significantly accumulated in gastric cancer cells, suggesting that the compound can induce ferroptosis in gastric cancer cells in a dose-dependent manner. Figure 12The semi-quantitative results of lipid reactive oxygen species (ROS) fluorescence were consistent with the confocal qualitative observations: Vilanterol significantly upregulated intracellular lipid ROS levels in AGS and HGC-27 cells, and this upregulation effect was dose-dependent. Figures 12C and 12D show the results of ferroptosis marker expression detection: transcriptional and protein level detection confirmed that Vilanterol dose-dependently upregulated HMOX1 expression while significantly inhibiting SLC7A11 and GPX4 expression, further supporting the evidence that Vilanterol can promote ferroptosis in gastric cancer cells. Figure EG shows that Vilanterol treatment significantly enhanced green fluorescence in cells. After intervention with the ferroptosis-specific inhibitor Ferrostatin-1 (Fer-1) and the lipid antioxidant Liproxstatin-1 (Lipro) in combination with Vilanterol, the intensity of green fluorescence in cells significantly decreased, and the lipid peroxidation phenotype was significantly reversed. The results of flow cytometry quantitative detection of the average fluorescence intensity of lipid ROS were completely consistent with the confocal qualitative observations. Figures 12E–G show the inhibitor complementarity verification experiments: Vilanterol alone significantly enhanced the green fluorescence of lipid peroxidation in cells. After co-treatment with the ferroptosis-specific inhibitor Ferrostatin-1 (Fer-1) and the lipid antioxidant Liproxstatin-1 (Lipro), the green fluorescence intensity of cells decreased significantly, and the lipid peroxidation phenotype was effectively reversed. The trend of the flow cytometry quantitative detection of lipid ROS fluorescence intensity was consistent with the confocal qualitative results. Figure 12G shows that the CCK-8 cell viability experiment showed that Vilanterol alone significantly inhibited the proliferation of AGS and HGC-27 gastric cancer cells; while the combined intervention of Fer-1 or Lipro significantly restored cell viability. From the perspective of cell function, this confirms that the inhibitory effect of Vilanterol on the proliferation of gastric cancer cells is highly dependent on the activation of the ferroptosis pathway.
[0114] 4.8 Nude mouse tumorigenesis experiment to verify the anti-cancer effect of compound Vilanterol Trifenatate
[0115] The antitumor activity of vilanterol trifenatate in vivo was detected using a nude mouse tumorigenesis assay. AGS cells stably overexpressing PHF20 in logarithmic growth phase were digested, centrifuged, resuspended in phosphate-buffered saline (PBSS), and kept on ice. 4–6 week old BALB / c nude mice were selected and injected intraperitoneally with an equal volume of cell suspension to establish a subcutaneous xenograft model. The mice were housed in an SPF-protected environment, and their mental state and weight were regularly observed. Once subcutaneous tumors were visibly formed, and the tumor volume was expected to reach 100 mm² in 7–14 days, the model was considered complete.3 Following this, subsequent interventions began. Tumor-bearing nude mice were randomly divided into 5 groups of 5 mice each: a blank solvent control group, a low-dose Vilanterol (10 mg / kg) monotherapy group, a high-dose Vilanterol (20 mg / kg) monotherapy group, a Vilanterol 10 mg / kg combined with Fer-1 group, and a Vilanterol 20 mg / kg combined with Fer-1 group. Intraperitoneal injection was used, with Fer-1 and Vilanterol administered concurrently every two days for 14 consecutive days. After the treatment period, all mice were sacrificed, and subcutaneous tumor tissue was completely dissected from each group. Gross tumor specimens were photographed using a standardized grid scale for direct comparison of tumor growth and volume differences. All animal procedures strictly followed the experimental protocol approved by the laboratory's animal ethics committee.
[0116] Experimental results are as follows Figure 12 As shown in Figure G, the results showed that, compared with the control group, Vilanterol dose-dependently reduced the volume of the xenograft, with the high-dose group of 20 mg / kg showing a more prominent tumor-suppressing effect. However, after combined Fer-1 intervention, the in vivo tumor-suppressing effect of Vilanterol was significantly offset, and tumor growth was restored to a certain extent. This confirms at the in vivo level that the effect of Vilanterol in inhibiting the proliferation of gastric cancer xenografts depends on ferroptosis activation.
[0117] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. The application of the PHF20 gene in the preparation of tumor diagnostic products, characterized by: The nucleotide sequence of the PHF20 gene is shown in SEQ ID NO.
1.
2. The application of the PHF20 gene in the preparation of tumor prognostic assessment products, characterized by: The nucleotide sequence of the PHF20 gene is shown in SEQ ID NO.
1.
3. A biomarker for screening the probability of tumor incidence and assessing prognosis, characterized in that: Including the expression level of the PHF20 gene, the nucleotide sequence of which is shown in SEQ ID NO.1; High expression of the PHF20 gene indicates a high probability of tumor development and a poor prognosis.
4. A tumor diagnostic product, characterized in that: Including reagents for detecting PHF20 gene expression levels; The nucleotide sequence of the PHF20 gene is shown in SEQ ID NO.
1.
5. The application of a reagent that inhibits PHF20 gene expression in the preparation of tumor therapeutic drugs, characterized in that: The nucleotide sequence of the PHF20 gene is shown in SEQ ID NO.
1.
6. A shRNA that inhibits the expression of a PHF20 gene, characterized in that It is at least one of the following: shPHF20#1, its positive strand nucleotide sequence is: 5'-TGCTGGGACAGTCCTTATTTA-3'; The antisense strand nucleotide sequence is: 5'-TAAATAAGGACTGTCCCAGCA-3'; shPHF20#2, its positive strand nucleotide sequence is: 5'-GTGGGTAATGCTAGGCCTAAA-3'; The antisense strand nucleotide sequence is: 5'-TTTAGGCCTAGCATTACCCAC-3'; Analogs of shPHF20#1 or shPHF20#2 that still retain the function of inhibiting PHF20 gene expression, obtained through base insertion, deletion, or substitution.
7. A vector for inhibiting PHF20 gene expression, characterized in that: This includes the nucleotide sequence of the shRNA that inhibits the expression of the PHF20 gene.
8. The application of the shRNA that inhibits PHF20 gene expression and / or the vector that inhibits PHF20 gene expression in the preparation of tumor therapeutic drugs.
9. The use of Torachrysone 8-glucoside in the preparation of PHF20 inhibitors and / or tumor therapeutic drugs, characterized in that: The structural formula of Torachrysone 8-glucoside is shown below: 。 10. A tumor treatment drug, characterized in that: This includes the aforementioned shRNA that inhibits PHF20 gene expression, vectors that inhibit PHF20 gene expression, and / or Torachrysone 8-glucoside.
